Form 4: Puma Biotechnology CFO Maximo Nougues Sells Shares Under 10b5-1 Plan

Maximo Nougues, CFO of Puma Biotechnology, sold 5,295 shares of common stock at an average price of $3.2685 under a pre-arranged 10b5-1 trading plan.

Summary

• On July 2, 2024, Maximo F. Nougues, the Chief Financial Officer of Puma Biotechnology, Inc. (PBYI), sold 5,295 shares of common stock.
• The sale was executed under a pre-existing 10b5-1(c) trading plan adopted on December 14, 2020.
• The shares were sold at a weighted average price of $3.2685, with individual transaction prices ranging from $3.2601 to $3.3101.
• Following the transaction, Nougues directly owns 166,678 shares of Puma Biotechnology common stock.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing regarding an insider stock sale under a pre-arranged plan. It is neutral in tone and doesn't convey any specific positive or negative sentiment about the company's performance or prospects.

Industry Context

This is a routine disclosure of an insider stock sale under a pre-arranged trading plan, which is a common practice among corporate executives to avoid accusations of insider trading. It doesn't necessarily reflect a change in the executive's confidence in the company.

Stakeholder Impact

• The stock sale by a high-ranking officer could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates